In recent years, significant advances have been made regarding the treatment of patients with chronic graft-vs-host disease, with investigators developing an understanding of the pathophysiology of the disease, as well as how to integrate novel treatment modalities.
In patients with advanced RET fusion–positive non-small cell lung cancer, pralsetinib demonstrated promising results regardless of previous therapies.
Mobocertinib improved patient-reported outcomes in those with previously treated non–small cell lung cancer whose tumors harbored EGFR exon 20 insertion mutations.
ADP-A2AFPspecific peptide enhanced affinity receptor T cells were associated with an acceptable safety profile and elicited antitumor activity in patients with advanced hepatocellular carcinoma.
Nivolumab elicited a prolonged clinical benefit in patients with advanced hepatocellular carcinoma regardless of prior sorafenib.
Triplet regimens leveraging novel agents targeted at overcoming mechanisms of resistance in combination with immune checkpoint inhibitors and anti-angiogenic therapies represent the next frontier in hepatocellular carcinoma.
David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).
The combination of atezolizumab and bevacizumab elicited an improved overall survival benefit compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma, according to findings from an exploratory subgroup analysis of the phase 3 IMbrave150 trial.
Biomarkers of response to immunotherapy, characterized by high interferon signaling and expression of MHC-II related genes, predicted for improved survival in patients with advanced hepatocellular carcinoma following immediate treatment with a PD-1 inhibitor but not in those who had first received treatment with a TKI.
Arndt Vogel, MD, discusses the utility of frontline lenvatinib or sorafenib in hepatocellular carcinoma.
Amit Singal, MD, discusses the results of a study evaluating the utilization of a mailed surveillance outreach program in hepatocellular carcinoma.
Nicole Rich, MD, discusses the prevalence of cachexia in hepatocellular carcinoma.
The addition of selective internal radiation therapy with Y90 resin microspheres to gemcitabine/cisplatin resulted in a median overall survival of 21.6 months for patients with inoperable intrahepatic cholangiocarcinoma, according to prospective phase 2 data.
Combining durvalumab and tremelimumab plus transcatheter arterial chemoembolization or radiofrequency ablation was found to be both efficacious and safe as a treatment for patients with advanced hepatocellular carcinoma, according to results of a pilot study.
Josep M. Llovet, MD, discusses the importance of identifying biomarkers of response to checkpoint inhibitors for patients with hepatocellular carcinoma, as well as future research directions.
Data that emerged from the 2021 ASCO Annual Meeting represent potential paradigm shifts for patients with advanced melanoma.
Stephen M. Ansell, MD, PhD, discusses recent progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.
The majority of patients with newly diagnosed chronic lymphocytic leukemia have better outcomes with BTK inhibitors compared with standard chemoimmunotherapy, making them the logical choice for frontline therapy.
Zanubrutinib demonstrated clinical activity and tolerability in previously treated patients with B-cell malignancies who were intolerant to therapy with ibrutinib and/or acalabrutinib, according to results of the phase 2 BGB-3111-215 trial.
As more CAR T-cell therapies are approved for the treatment of patients with hematologic malignancies, adopting management strategies for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome using newly standardized grading criteria is an important component of utilizing these products in practice.
Acalabrutinib, alone or in combination with obinutuzumab, demonstrated superior efficacy and an acceptable safety profile in patients with treatment-naïve chronic lymphocytic leukemia.
The combination of loncastuximab tesirine-lpyl and ibrutinib displayed encouraging antitumor activity with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma.
Alison J. Moskowitz, MD, discusses recent developments made in the Hodgkin lymphoma paradigm, shared advice for optimal stratification, and spotlighted potential emerging prognostic markers that might further help to guide treatment decisions.
CAR T-cell therapy has proven to be an effective treatment option in non-Hodgkin lymphoma subtypes, such as diffuse large B-cell lymphoma, and mantle cell lymphoma.
Five-year survival rates in renal cell carcinoma are drastically improving due to recent regulatory approvals of combination therapies involving checkpoint blockade and VEGF TKIs.
“Smarter screening” and a better understanding of the breast cancers women of color are more likely to develop are all crucial to helping these patients survive this disease at the same rates as their White counterparts.
With more oral cancer therapies available, the importance of medication adherence and education must be recognized.
Understanding the functionality and naming convention of biosimilars vs their biologic counterparts are important concepts to utilizing these agents in oncology, according to a presentation given by Teresa Knoop, MSN, RN, AOCN, during the 5th Annual School of Nursing Oncology Meeting.
Data that were presented during the 2021 ASCO Annual Meeting shed light on new therapeutic strategies, and treatment considerations that are expanding the paradigms of gastrointestinal malignancies.
Sara A. Hurvitz, MD, highlights that although differences in overall survival and toxicity profile could inform treatment selection with CDK4/6 inhibitors, optimal sequencing with these agents remains uncertain.
